Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001). The most common adverse effects were rash and diarrhoea. In conclusion erlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC.
Lung cancer is one of the most common human malignant diseases and the leading cause of cancer-related deaths worldwide [1] . Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer [2] . NSCLC is divided into four major histological subtypes including adenocarcinoma (ADC), squamous cell carcinoma (SCC), large-cell carcinoma (LCC) and not otherwise specified (NOS) [3] . The most frequent histological subtype is ADC, but SCC accounts for approximately 25-30% of all lung cancer cases [4] . Considerable progress in the field of NSCLC has been reached and several new effective agents have been approved for the treatment of patients with advanced-stage NSCLC including pemetrexed, bevacizumab, gefitinib, crizotinib and erlotinib. The treatment efficacy of pemetrexed and bevacizumab is limited to patients with non-squamous histology [5, 6, 7] . The treatment efficacy of gefitinib and crizotinib is limited to patients harbouring specific genetic alterations occurring predominantly in patients with ADC such as activating epidermal growth factor receptor (EGFR) mutations in the case of gefitinib [8, 9] and anaplastic lymphoma kinase (ALK) translocations in the case of crizotinib [10, 11] . Erlotinib is the only one of the novel targeted agents used for the treatment of patients with advanced-stage SCC in current clinical practice [12] . Erlotinib is an orally administered low-molecular tyrosine kinase inhibitor targeting epidermal growth factor receptors. Results of the randomised phase III BR.21 and SATURN clinical trials showed that erlotinib treatment was effective even in patients with SCC, and a significant survival benefit was achieved in this group [13, 14] . Despite several studies evaluating erlotinib efficacy in terms of clinical practice have been published recently, analysis performed on a large cohort of patients is still lacking. Thus we conducted this large retrospective study based on clinical experience aiming to prove erlotinib's efficacy in the treatment of patients with advanced-stage SCC.
Patients and methods
Study design and treatment. We analysed data of patients with cytologically or histologically confirmed locally-advanced (IIIB) or metastatic (IV) stage squamous cell NSCLC. Patients were diagnosed and treated at the following three departments: Department of Tuberculosis and Respiratory Diseases, Medical School and Teaching Hospital Pilsen; Department of Pneumology and Thoracic Surgery, University Hospital Prague-Bulovka and Pulmonary Department, Faculty of Medicine and University Hospital Hradec Kralove. Patients were treated with oral erlotinib, which was approved at a standard daily dose of 150 mg; dose interruption or reduction (in 50 mg/day decrements) was permitted in the event of treatment-related toxicity. The treatment was continued until disease progression or development of intolerable toxic effects.
Clinical assessments and statistical analysis. The treatment was prospectively monitored and the clinical course of patients was continuously assessed at specific time points. Clinical follow-up exams included physical examination, plain chest skiagram and routine laboratory tests. These were performed every 3-4 weeks. CT or PET-CT exams were performed after 2 or 3 months of treatment with erlotinib. The best treatment response was assessed by investigators in terms of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) [15] . The overall response rate (ORR) was defined as the sum of CR and PR. The disease control rate (DCR) was defined as the sum of CR, PR and SD. Standard frequency tables and summary statistics , i.e. median and percentiles, were used to describe sample data set. Progression-free survival (PFS) was determined from the date of erlotinib initiation until the date of first documented progression or death. Overall survival (OS) was determined from the date of erlotinib initiation until the date of death. Adverse events and serious adverse events were recorded and classified by grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. [16] . The visualizations of PFS and OS as well as the estimations of survival probabilities were performed using Kaplan-Meier survival curves; all point estimates were accompanied with 95% confidence intervals. The differences in survival were tested using the log-rank test. As a level of statistical significance, P=0.05 was used.
EGFR mutation analysis. Tumor specimens acquired during an initial bronschoscopic examination were evaluated by a senior cytologist using a regular giemsa staining. In a few cases a tumor biopsy was processed into formalin-fixed paraffin embedded (FFPE) histology sections. The cytology slides or FFPE sections, were submitted for molecular genetic testing, including detection of somatic mutations in the EGFR gene. If necessary, tumor cells were carefully selected and removed from the samples by laser micro-dissection using a P.A.L.M. micro-laser instrument [Carl Zeiss MicroImaging GmbH, Germany]. The micro-dissected cells were collected directly into the PCR buffer and processed without a special DNA extraction step. In all other cases the DNA was extracted from tissue cells by a standard spin column procedure using JetQuick Tissue DNA Isolation Kit [GENOMED GmbH, Loehne, Germany]. The mutations in exons 19 and 21 of the EGFR gene were analysed by Genoscan EGFR kits [Genomac International, Prague, Czech Republic] utilizing a denaturing capillary electrophoresis (DCE) technique on an ABI PRISM 3100 16-capillary genetic analyzer. Detected mutations were identified by regular DNA sequencing using a BigDye v 3.0 chemistry (Applied Biosystems, Foster City, CA). In rare cases, where the overall fraction of mutated DNA was below the 20% minimum required for DNA sequencing, mutation was identified indirectly after forming only a homoduplex fragment with a given known mutation reference standard. Response and survival. CR was achieved in 1 (0.3%) patient, PR was achieved in 28 (7.5%) patients, SD was achieved in 198 (52.8%) patients, PD occurred in 102 (27.2%) patients and the best treatment response was not evaluated in 46 (12.3%) patients. The ORR and DCR were 7.8% and 60.5%, respectively. The results of the best treatment response are summarized in Table 2 . The median of PFS was 3.0 months (95% CI 2.6-3.3) [Fig. 1A ] and the median of OS was 7.6 months (95% CI 6.5-8.7) [Fig. 1B ]. The median PFS of patients with CR/PR, SD and PD was 7.6 (95% CI 4.2-11.1), 3.9 (95% CI 3.4-4.4) and 1.0 months (95% CI 0.9-1.1), respectively; the difference was statistically significant (P<0.001) [Fig. 1C ]. The median OS of patients with CR/PR, SD and PD was 13.3 (95% CI 10.3-16.3), 10.9 (95% CI 9.5-12.2) and 3.8 months (95% CI 2.8-4.7), respectively; the difference was statistically significant (P<0.001) [Fig. 1D ].
Results
Safety and tolerability. Treatment was accompanied by an adverse event (AE) in 186/375 (49.6%) patients. The most commonly recorded AE was skin rash, occurring in 156/375 Fig.2A ]. The median OS of patients with skin rash was 11.6 vs. 5.5 months of patients without skin rash; the difference was statistically significant (P<0.001) [Fig.2B ]. The median PFS of never/former-smokers was 3.1 vs. 2.8 months in current-smokers; the difference was statistically significant (P=0.028) [Fig.2C ]. The median OS of never/ former-smokers was 8.4 vs. 6.6 months in current-smokers; the difference was not statistically significant (P=0.255) [Fig.2D ]. The median PFS of patients with ECOG PS 0/1 was 3.7 vs. 2.1 months of patients with ECOG PS 2/3; the difference was statistically highly significant (P<0.001) [Fig.2E ]. The median OS of patients with ECOG PS 0/1 was 10.7 vs. 5.8 months of patients with ECOG PS 2/3; the difference was statistically highly significant (P<0.001) [Fig.2F ]. The median PFS of patients treated in the first, second, third or higher treatment line were 3.6 months (95% CI 2.1-5.1), 2.8 months (95% CI 2.2-3.3) and 3.0 months (95% CI 2.3-3.6) respectively. The median OS of patients treated in the first, second, third or higher treatment line were 9.1 months (95% CI 7.2-11.0), 7.0 months (95% CI 5.4-8.5) and 7.8 months (95% CI 6.5-9.1) respectively. There was no statistically significant difference in PFS (P=0.489) nor in OS (P=0.372) between these groups. EGFR mutation analysis. 87/375 (23.2%) patients had adequate specimens for EGFR mutation analysis and were successfully tested. Activating EGFR mutations were found in 4 (4.6%) patients including 2 exon 19 deletions and 2 exon 21 point mutations, termed L858R. Among patients harboring the activating EGFR mutation, there were 2 males and 2 females, all with a positive smoking history, 1 PR and 3 SD were achieved, PFS was 3.8, 3.6, 3.0 and 5.0 months respectively and OS was 27.0, 25.5, 11.25 and 6.33 months respectively. Because of the low number of patients harboring the activating EGFR mutation, statistical analysis could not be performed.
Discussion
In this study, ORR and DCR were achieved in 7.8 and 60.5% patients, respectively; the median PFS and OS were 3.0 and 7.6 months, respectively. In comparison with the data recently reported by Tseng et al. and Chiang et al. focusing on treatment efficacy of erlotinib in patients with advancedstage SCC, our study showed lower ORR (7.8% vs. 17.4% and 16.2%), but higher DCR (60.5% vs. 27.2% and 51.4%) and longer PFS (3.0 vs. 1.7 and 2.0 months) [17, 18] . On the other hand, our results are similar to those previously reported by Reck et al., who reported data of a phase IV trial of erlotinib in advanced NSCLC showing ORR between 4 and 17% and PFS between 2.3 and 3.0 months in a subgroup of patients with SCC [19] . Outstanding survival times were reached especially in patients achieving CR or PR, where the median PFS was 7.6 months and median OS was 13.3 months. The treatment was safe and well-tolerated. The most common AEs were skin rash (41.6%) and diarrhoea (17.1%); no ILD-like events or cases of toxic death were reported. We showed longer survival of patients occurring with skin rash compared to those without (PFS: 3.6 vs. 2.4 months, P=0.007; OS: 11.6 vs. 5.5 months of patients, P<0.001). Thus we confirmed the role of skin rash as a marker of erlotinib efficacy, a fact that has been previously reported [20] [21] [22] . An important finding in our study was longer PFS of never-smokers or former-smokers in comparison with current-smokers (3.1 vs. 2.8 months, P=0.028). Hamilton et al. reported previously that smoking could significantly influence the pharmacokinetics of erlotinib [23] . Patients receiving erlotinib should be strongly advised to stop smoking. We showed longer survival of patients with PS 0 or 1 in comparison with those with PS 2 or 3 (PFS: 3.7 vs. 2.1 months, P<0.001; OS: 10.7 vs. 5.8 months, P<0.001). These results suggest that PS is a strong prognostic factor and that the efficacy of erlotinib treatment in patients with higher PS is limited. On the other hand, the fact should be mentioned that patients with higher PS are not suitable for chemotherapy, thus erlotinib remains the only treatment option for them. Activating EGFR mutations were found in 4/87 (4.9%) patients, a similar EGFR mutation frequency in SCC has been previously reported by Miyamae et al. [24] . Among patients harboring activating EGFR mutation, 1 PR and 3 SD were achieved, but relatively short PFS ranging between 3.0 and 5.0 months was reached. Activating EGFR mutations have been well-known as a strong predictive marker of efficacy of treatment with EGFR-TKIs in patients with advanced NSCLC and they are commonly found in ADC, contrasting with their scarce occurrence in SCC [25] [26] [27] [28] [29] [30] [31] [32] [33] . Shukuya et al. have published an interesting study demonstrating that the treatment efficacy of gefitinib was significantly inferior in non-adenocarcinoma NSCLC patients harboring activating EGFR mutations compared to those with ADC [34] . Thus the predictive role of activating EGFR mutations in SCC still remains unclear and further research is needed to answer this interesting question.
In conclusion, erlotinib is effective and well-tolerated option for the treatment of patients with locally-advanced or metastatic stage squamous cell NSCLC.
